US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

OS Therapies

1.82

-0.0200-1.09%

Post-market: 1.78-0.0400-2.20%19:38 EDT

Volume:186.59K

Turnover:335.11K

Market Cap:51.14M

PE:-2.22

High:1.87

Open:1.79

Low:1.73

Close:1.84

Loading ...

Overview Company News Filings

Os Therapies: Intends to Initiate Rolling Bla Submission With Potential to GET Accelerated Approval as Early as Year-End 2025

THOMSON REUTERS

Os Therapies: Applies for Meeting per FDA Suggestion Received on April 2, 2025

THOMSON REUTERS

OS Therapies Requests Meeting with FDA to Gain Agreement on Surrogate Endpoint(s) for Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma

OS Therapies Incorporated (OSTX) Initiated with a Buy at Lake Street

OS Therapies Initiated at Buy by Lake Street

OS Therapies to Host Analyst Day at NYSE on April 7, 2025

OS Therapies initiated with a Buy at Lake Street

OS Therapies 2024 EPS $(0.88) May Not Be Comparable To $(1.46) YoY

Press Release: OS Therapies Reports Full Year 2024 Financial Results and Provides Business Update

OS Therapies Is Maintained at Buy by D. Boral Capital

OS Therapies provides regulatory update on OST-HER2

Os Therapies Provides Regulatory Update on Rare Pediatric Cancer Immunotherapy Candidate Ost-Her2 for Human Osteosarcoma

THOMSON REUTERS

Os Therapies - New Canine Elite Responder Biomarkers Added to Human Biomarker Strategy

THOMSON REUTERS

Os Therapies - Dialogue Open With FDA in Preparation for End of Phase 2 Meeting Request

THOMSON REUTERS

OS Therapies Provides Regulatory Update on Rare Pediatric Cancer Immunotherapy Candidate OST-HER2 for Human Osteosarcoma

OS Therapies (OSTX): Among the Penny Stocks With Huge Upside Potential According to Analysts

OS Therapies to Attend The Jones Healthcare and Technology Innovation Conference

OS Therapies Awarded OST-HER2 Clinical Trial Data Presentation at MIB Agents FACTOR Osteosarcoma Conference

OS Therapies schedules Scientific Advice Meeting for OST-HER2 in Q3

OS Therapies Schedules United Kingdom’s Medicines and Healthcare products Regulatory Agency's (MHRA) Scientific Advice Meeting in the Third Quarter of 2025 for Review of its OST-HER2 Immunotherapy Candidate for Osteosarcoma

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/OSTX/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OSTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OSTX\",,,,,undefined,":{"symbol":"OSTX","market":"US","secType":"STK","nameCN":"OS Therapies","latestPrice":1.82,"timestamp":1749844800000,"preClose":1.84,"halted":0,"volume":186589,"hourTrading":{"tag":"盘后","latestPrice":1.78,"preClose":1.82,"latestTime":"19:38 EDT","volume":1395,"amount":2554.6518,"timestamp":1749857925129},"delay":0,"floatShares":18778400,"shares":28097697,"eps":-0.819717,"marketStatus":"Market Closed","change":-0.02,"latestTime":"06-13 16:00:00 EDT","open":1.79,"high":1.87,"low":1.73,"amount":335107.0521604,"amplitude":0.076087,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.819717,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750060800000},"marketStatusCode":7,"adr":0,"listingDate":1719460800000,"exchange":"AMEX","adjPreClose":1.84,"preHourTrading":{"tag":"盘前","latestPrice":1.7802,"preClose":1.863,"latestTime":"09:27 EDT","volume":10344,"amount":18630.5763312,"timestamp":1749821265289},"postHourTrading":{"tag":"盘后","latestPrice":1.78,"preClose":1.82,"latestTime":"19:38 EDT","volume":1395,"amount":2554.6518,"timestamp":1749857925129},"volumeRatio":0.31820578656515647},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OSTX\",,,,,undefined,":{"symbol":"OSTX","floatShares":18778400,"roa":"-263.81%","roe":"--","lyrEps":-0.879526,"volumeRatio":0.31820578656515647,"shares":28097697,"dividePrice":0,"high":1.87,"amplitude":0.076087,"preClose":1.84,"low":1.73,"week52Low":1.12,"pbRate":"-12.21","week52High":7,"institutionHeld":0,"latestPrice":1.82,"eps":-0.819717,"divideRate":0,"volume":186589,"delay":0,"ttmEps":-0.819717,"open":1.79,"prevYearClose":4.28,"prevWeekClose":1.67,"prevMonthClose":1.53,"prevQuarterClose":1.54,"fiveDayClose":1.67,"twentyDayClose":1.66,"sixtyDayClose":1.52},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OSTX\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2525090224","title":"Os Therapies: Intends to Initiate Rolling Bla Submission With Potential to GET Accelerated Approval as Early as Year-End 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2525090224","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525090224?lang=en_us&edition=fundamental","pubTime":"2025-04-07 18:00","pubTimestamp":1744020005,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250407:nFWN3QL0XI:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2525090203","title":"Os Therapies: Applies for Meeting per FDA Suggestion Received on April 2, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2525090203","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525090203?lang=en_us&edition=fundamental","pubTime":"2025-04-07 18:00","pubTimestamp":1744020005,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250407:nFWN3QL0XI:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2525018533","title":"OS Therapies Requests Meeting with FDA to Gain Agreement on Surrogate Endpoint(s) for Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2525018533","media":"Business Wire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525018533?lang=en_us&edition=fundamental","pubTime":"2025-04-07 18:00","pubTimestamp":1744020000,"startTime":"0","endTime":"0","summary":"OS Therapies applies for meeting per FDA suggestion received on April 2, 2025. Based on prior FDA guidance, greater than 200 suitable matched lung metastatic osteosarcoma patient records identified from leading oncology centers in the US, UK and France for inclusion in OST-400, a Retrospective Longitudinal Study of Recurrent Osteosarcoma after Resection in Children and Young Adults. \"We are excited to meet with the FDA – and commence market access discussions - the goal of receiving Accelerated Approval for a Biologics License Application of OST-HER2 in the prevention or delay of recurrence lung metastatic osteosarcoma by year-end 2025,\" said Dr. Robert Petit, Chief Medical & Scientific Officer of OS Therapies. \"We believe that we have identified the comparator data necessary to address the comments from FDA regarding our prior BTD request. We expect this data will also be able support our application for Accelerated Approval. Our clinical and regulatory teams are diligently preparing ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/os-therapies-requests-meeting-fda-100000983.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4080","OST","OS","ADC","OSTX","BK4017","BK4139","BK4148","BK4231","DC","BK4097"],"gpt_icon":0},{"id":"2524969932","title":"OS Therapies Incorporated (OSTX) Initiated with a Buy at Lake Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2524969932","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524969932?lang=en_us&edition=fundamental","pubTime":"2025-04-04 01:06","pubTimestamp":1743699988,"startTime":"0","endTime":"0","summary":"OS Therapies Incorporated (OSTX – Research Report) received a Buy rating and a $19.00 price target from Lake Street analyst Chad Messer yesterday. ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/os-therapies-incorporated-ostx-initiated-with-a-buy-at-lake-street?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/os-therapies-incorporated-ostx-initiated-with-a-buy-at-lake-street?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2524185460","title":"OS Therapies Initiated at Buy by Lake Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2524185460","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524185460?lang=en_us&edition=fundamental","pubTime":"2025-04-02 20:23","pubTimestamp":1743596580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OSTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 02, 2025 08:23 ET (12:23 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2524649204","title":"OS Therapies to Host Analyst Day at NYSE on April 7, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2524649204","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524649204?lang=en_us&edition=fundamental","pubTime":"2025-04-02 19:40","pubTimestamp":1743594000,"startTime":"0","endTime":"0","summary":"NEW YORK, April 02, 2025----OS Therapies  , a clinical-stage immunotherapy and Antibody Drug Conjugate  biopharmaceutical company, today announced that the Company will be hosting an Analyst Day at the New York Stock Exchange in Lower Manhattan that will start at 10am on Monday, April 7, 2025.The Company intends to focus the Analyst Day discussion on:. OST-HER2 program for human recurrent, fully resected lung metastatic osteosarcoma that is being positioned for Accelerated Approval in late 2025. OST-HER2 program for canine osteosarcoma that is being positioned for conditional approval in the second half of 2025, and plans for full approval. OST-HER2 data in breast cancer, and other human solid tumors to be pursued immediately after approval of OST-HER2 in osteosarcoma. Additionally, the Company will review the pipeline of assets being acquired from Ayala Pharmaceuticals, and potential of our tunable drug conjugates  & antibody drug conjugates  platform.New York Stock Exchange, 18 Broad","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/os-therapies-host-analyst-day-114000741.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADC","BK4181","BK4588","BK4218","OSTX","BK4017","BK4097","BK4139","BK4231","BK4585","NYSE","HST","BK4080","OS","DC"],"gpt_icon":0},{"id":"2524311461","title":"OS Therapies initiated with a Buy at Lake Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2524311461","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524311461?lang=en_us&edition=fundamental","pubTime":"2025-04-02 19:20","pubTimestamp":1743592812,"startTime":"0","endTime":"0","summary":"Lake Street analyst Chad Messer initiated coverage of OS Therapies (OSTX) with a Buy rating and $19 price target Top line data from a Phase 2b tria...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/os-therapies-initiated-with-a-buy-at-lake-street?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/os-therapies-initiated-with-a-buy-at-lake-street?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2524773589","title":"OS Therapies 2024 EPS $(0.88) May Not Be Comparable To $(1.46) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2524773589","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524773589?lang=en_us&edition=fundamental","pubTime":"2025-04-01 04:33","pubTimestamp":1743453234,"startTime":"0","endTime":"0","summary":"Net loss per share in the full year 2024 was $0.88 on 12.377 million weighted average shares outstanding compared to full year 2023 where the Company delivered a loss of $1.46 per share on 5.429 million weighted average","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44571952/os-therapies-2024-eps-0-88-may-not-be-comparable-to-1-46-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"gpt_icon":0},{"id":"2524972201","title":"Press Release: OS Therapies Reports Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2524972201","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524972201?lang=en_us&edition=fundamental","pubTime":"2025-04-01 04:30","pubTimestamp":1743453000,"startTime":"0","endTime":"0","summary":"-- Full data from OST-HER2 Phase 2b osteosarcoma trial, including synthetic. control arm data being developed at the request of FDA to support a. Breakthrough Therapy Designation request, to be presented at MIB Factor. regulatory approval by year-end 2025, triggering issuance of a Priority. OS Therapies Inc.  , a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported full-year 2024 financial results ended December 31, 2024 and provided a business update.OS Therapies' lead product candidate, OST-HER2, is a cancer immunotherapy biologic drug candidate comprised of HER2 bioengineered form of the Lm that mimics a listeria infection of HER2 overexpressing cancer cells and triggers a strong, immune response against cancer cells expressing HER2. This off-the-shelf immunotherapy is designed to prevent metastasis, delay recurrence, kill primary tumors expressing HER2 and increase overall surv","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","BK4588","BK4097","BK4139","BK4017","BK4532","DC","IPO","BK4158","BK4231","BK4585","OS","OSTX","SAM","ADC"],"gpt_icon":0},{"id":"2523499189","title":"OS Therapies Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2523499189","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523499189?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:40","pubTimestamp":1743424800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OSTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 31, 2025 08:40 ET (12:40 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"gpt_icon":0},{"id":"2523945190","title":"OS Therapies provides regulatory update on OST-HER2","url":"https://stock-news.laohu8.com/highlight/detail?id=2523945190","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523945190?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:55","pubTimestamp":1743422120,"startTime":"0","endTime":"0","summary":"OS Therapies (OSTX) provided a regulatory update for its OST-HER2 listeria monocytogenes immunotherapeutic cancer biologic drug candidate in the pr...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/os-therapies-provides-regulatory-update-on-ost-her2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/os-therapies-provides-regulatory-update-on-ost-her2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OSTX","OST","BK4139","BK4148"],"gpt_icon":0},{"id":"2523948456","title":"Os Therapies Provides Regulatory Update on Rare Pediatric Cancer Immunotherapy Candidate Ost-Her2 for Human Osteosarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2523948456","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523948456?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:40","pubTimestamp":1743421242,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nFWN3QE10E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2523948282","title":"Os Therapies - New Canine Elite Responder Biomarkers Added to Human Biomarker Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2523948282","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523948282?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:40","pubTimestamp":1743421242,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nFWN3QE10E:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2523594845","title":"Os Therapies - Dialogue Open With FDA in Preparation for End of Phase 2 Meeting Request","url":"https://stock-news.laohu8.com/highlight/detail?id=2523594845","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523594845?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:40","pubTimestamp":1743421242,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nFWN3QE10E:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2523456169","title":"OS Therapies Provides Regulatory Update on Rare Pediatric Cancer Immunotherapy Candidate OST-HER2 for Human Osteosarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2523456169","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523456169?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:40","pubTimestamp":1743421200,"startTime":"0","endTime":"0","summary":"New canine elite responder biomarkers added to human biomarker strategy. NEW YORK, March 31, 2025----OS Therapies  , a clinical-stage immunotherapy and Antibody Drug Conjugate  biopharmaceutical company, today provided a regulatory update for its OST-HER2 listeria monocytogenes  immunotherapeutic cancer biologic drug candidate in the prevention or delay of fully-resected, recurrent, lung metastatic osteosarcoma.\"We are making rapid progress in putting together an appropriate data package to achieve accelerated approval for OST-HER2 given the feedback we’ve received to date from the FDA,\" said Paul Romness, MHP, Chairman & CEO of OS Therapies. \"We know one of the US government’s stated priorities is to treat deadly childhood cancers, and we believe that OST-HER2 for osteosarcoma aligns well with that mission.\". The Company initiated regulatory correspondence with the US Food & Drug Administration  and the United Kingdom’s Medicines and Healthcare products Regulatory Agency  in the first","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/os-therapies-provides-regulatory-rare-114000177.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NICE","OS","BK4148","OSTX","BK4139","ADC","DC","BK4017","BK4543","IE00BFMHRM44.USD","BK4231","BK4566","OST","BK4080","BK4097","BK4023"],"gpt_icon":0},{"id":"2521055402","title":"OS Therapies (OSTX): Among the Penny Stocks With Huge Upside Potential According to Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2521055402","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521055402?lang=en_us&edition=fundamental","pubTime":"2025-03-23 20:49","pubTimestamp":1742734185,"startTime":"0","endTime":"0","summary":"We recently published a list of 10 Penny Stocks With Huge Upside Potential According To Analysts. In this article, we are going to take a look at where OS Therapies Incorporated  stands against other penny stocks with the biggest upside potential.Further insights came from Chris Retzler, portfolio manager for Needham’s Small Cap Growth Fund, who shared his outlook for small-caps on CNBC’sSquawk Boxon January 17, 2025. He noted that small-cap companies are looking for policy certainty, and once the new administration’s direction becomes clearer, we could see growth accelerate. Globally, the EV sector is thriving, even as it faces some hurdles in the United State","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/os-therapies-ostx-among-penny-124945078.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2521400452","title":"OS Therapies to Attend The Jones Healthcare and Technology Innovation Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2521400452","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521400452?lang=en_us&edition=fundamental","pubTime":"2025-03-21 19:40","pubTimestamp":1742557200,"startTime":"0","endTime":"0","summary":"NEW YORK, March 21, 2025----OS Therapies  , a clinical-stage immunotherapy and Antibody Drug Conjugate  biopharmaceutical company, today announced that Paul Romness, CEO, and Gerald Commissiong, CBO will be accepting meetings with registered investors at The Jones Healthcare and Technology Innovation Conference. The conference is being held on April 8-9, 2025 at the Venetian Resort in Las Vegas. The Company’s participation aligns with its prioritization of advancements in healthcare and technology while connecting with other investors.Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as \"anticipate,\" \"expect,\" \"intend,\" \"may,\" \"will,\" \"should\" or other comparable terms involve risks and uncertainties because they rela","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/os-therapies-attend-jones-healthcare-114000511.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4097","BK4137","BK4231","OS","BK4080","OSTX","BK4139","HCSG","ADC"],"gpt_icon":0},{"id":"2519838093","title":"OS Therapies Awarded OST-HER2 Clinical Trial Data Presentation at MIB Agents FACTOR Osteosarcoma Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2519838093","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519838093?lang=en_us&edition=fundamental","pubTime":"2025-03-13 19:40","pubTimestamp":1741866000,"startTime":"0","endTime":"0","summary":"NEW YORK, March 13, 2025----OS Therapies, Inc. , a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has been awarded a presentation slot at the MIB Agents Factor Osteosarcoma Conference to be held June 26-28, 2025 in Salt Lake City, Utah. Key data will be presented from the Company’s Phase 2b clinical trial of OST-HER2 in the prevention of recurrent, fully resected, lung metastatic osteosarcoma. This data will be compared with a newly created regulatorily compliant synthetic control group comprised of case matched controls that will be used for the Company’s US Food & Drug Administration  OST-HER2 Biologics License Application  submission. Equivalent submissions with international regulatory authorities will be made in order to gain commercial marketing authorization. MIB Agents FACTOR is the most important annual osteosarcoma conference bringing together the leading osteosarcoma researchers, clini","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/os-therapies-awarded-ost-her2-114000281.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4148","BK4231","BK4080","DC","OS","BK4097","BK4017","OSTX","ADC","OST","BK4139"],"gpt_icon":0},{"id":"2518748676","title":"OS Therapies schedules Scientific Advice Meeting for OST-HER2 in Q3","url":"https://stock-news.laohu8.com/highlight/detail?id=2518748676","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518748676?lang=en_us&edition=fundamental","pubTime":"2025-03-11 19:51","pubTimestamp":1741693876,"startTime":"0","endTime":"0","summary":"OS Therapies (OSTX) announced that it has scheduled a Scientific Advice Meeting in the third quarter of 2025 to discuss the Innovative Licensing an...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/os-therapies-schedules-scientific-advice-meeting-for-ost-her2-in-q3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/os-therapies-schedules-scientific-advice-meeting-for-ost-her2-in-q3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4148","OST","OSTX","BK4139"],"gpt_icon":0},{"id":"2518418748","title":"OS Therapies Schedules United Kingdom’s Medicines and Healthcare products Regulatory Agency's (MHRA) Scientific Advice Meeting in the Third Quarter of 2025 for Review of its OST-HER2 Immunotherapy Candidate for Osteosarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2518418748","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518418748?lang=en_us&edition=fundamental","pubTime":"2025-03-11 19:40","pubTimestamp":1741693200,"startTime":"0","endTime":"0","summary":"NEW YORK, March 11, 2025----OS Therapies, Inc. , a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has scheduled a Scientific Advice Meeting  in the third quarter of 2025 to discuss the Innovative Licensing and Access Pathway  with the United Kingdom’s  Medicines and Healthcare products Regulatory Agency  for OST-HER2, its immunotherapy candidate for the prevention of recurrence of metastases in osteosarcoma. The Company released positive Phase 2b data in January 2025 that demonstrates statistically significant results in the primary endpoint of the study, 12-month event free survival . The meeting with MHRA has been scheduled to position the Company to bring OST-HER2 to market in the UK in 2025.\"Today’s announcement marks the beginning of the regulatory process required to bring our OST-HER2 immunotherapy to market globally,\" stated OS Therapies’ CEO Paul Romness. \"As we prepare for regulatory in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/os-therapies-schedules-united-kingdom-114000512.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4231","OSTX","OST","BK4097","HCSG","BK4139","UK","BK4585","OS","SAM","BK4588","BK4137","DC","BK4532","BK4205","BK4158","BK4080","UBCP","BK4017","BK4528","ADC","BK4148","MDCO","BK4211","BK4233"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":3,"totalSize":105,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OSTX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OSTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OSTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":4,"updateTime":1743652800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/OSTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"OSTX","date":"2025-06-13","current":-4.574874,"percent":0.80543,"low":-14.897496,"twenty":-11.315425,"median":-7.167274,"eighty":-4.590507,"high":-2.731469,"avg":-7.723832,"sd":3.415038,"marketCap":51699762},"quantilePoints":[{"date":"2024-06-14","current":-13.217965,"twenty":-13.216533,"median":-13.214385,"eighty":-13.212238,"marketCap":102988885},{"date":"2024-06-21","current":-10.574372,"twenty":-13.217965,"median":-13.214385,"eighty":-12.156232,"marketCap":82391108},{"date":"2024-06-28","current":-13.217965,"twenty":-13.217965,"median":-13.217965,"eighty":-13.210806,"marketCap":102988885},{"date":"2024-08-02","current":-6.458845,"twenty":-13.217965,"median":-13.217965,"eighty":-11.101659,"marketCap":50324634},{"date":"2024-08-09","current":-8.117559,"twenty":-13.217965,"median":-10.433676,"eighty":-8.215548,"marketCap":63248641},{"date":"2024-08-16","current":-10.993719,"twenty":-13.216533,"median":-10.29298,"eighty":-8.15204,"marketCap":70975778},{"date":"2024-08-23","current":-13.004275,"twenty":-13.182439,"median":-10.833368,"eighty":-8.309008,"marketCap":83955991},{"date":"2024-08-30","current":-11.710317,"twenty":-13.188909,"median":-11.710317,"eighty":-8.610078,"marketCap":75602161},{"date":"2024-09-06","current":-12.939577,"twenty":-13.217965,"median":-12.391225,"eighty":-8.620371,"marketCap":83538300},{"date":"2024-09-13","current":-11.32213,"twenty":-13.217965,"median":-12.261039,"eighty":-9.289415,"marketCap":73096012},{"date":"2024-09-20","current":-11.483875,"twenty":-13.217965,"median":-11.710317,"eighty":-10.29298,"marketCap":74140241},{"date":"2024-09-27","current":-9.575287,"twenty":-13.210806,"median":-11.435351,"eighty":-9.575287,"marketCap":61818342},{"date":"2024-10-04","current":-9.727327,"twenty":-13.101322,"median":-11.354479,"eighty":-9.316172,"marketCap":62799917},{"date":"2024-10-11","current":-9.931126,"twenty":-13.068973,"median":-11.192735,"eighty":-9.413543,"marketCap":64115645},{"date":"2024-10-18","current":-9.769381,"twenty":-13.068973,"median":-10.859351,"eighty":-9.542938,"marketCap":63071416},{"date":"2024-10-25","current":-9.413543,"twenty":-13.004275,"median":-10.610453,"eighty":-9.542938,"marketCap":60774113},{"date":"2024-10-31","current":-8.782738,"twenty":-12.952517,"median":-10.592413,"eighty":-9.394069,"marketCap":56701621},{"date":"2024-11-08","current":-9.085848,"twenty":-12.836061,"median":-10.29298,"eighty":-9.218608,"marketCap":58658505},{"date":"2024-11-15","current":-7.116768,"twenty":-12.603148,"median":-10.141393,"eighty":-8.950952,"marketCap":45946065},{"date":"2024-11-22","current":-5.272053,"twenty":-12.423258,"median":-9.769381,"eighty":-8.605027,"marketCap":38782655},{"date":"2024-11-29","current":-6.178419,"twenty":-12.235002,"median":-9.759676,"eighty":-8.507772,"marketCap":45450128},{"date":"2024-12-06","current":-5.370028,"twenty":-11.917351,"median":-9.716005,"eighty":-8.143742,"marketCap":39503383},{"date":"2024-12-13","current":-12.876517,"twenty":-11.917351,"median":-9.704683,"eighty":-7.804035,"marketCap":94723165},{"date":"2024-12-20","current":-11.288606,"twenty":-11.937313,"median":-9.73218,"eighty":-8.125896,"marketCap":83042057},{"date":"2024-12-27","current":-14.738704,"twenty":-12.001827,"median":-9.761941,"eighty":-8.139646,"marketCap":108421919},{"date":"2025-01-03","current":-12.068126,"twenty":-12.384347,"median":-9.850254,"eighty":-8.168424,"marketCap":88776420},{"date":"2025-01-10","current":-14.782011,"twenty":-12.810182,"median":-10.086184,"eighty":-8.234384,"marketCap":108740495},{"date":"2025-01-17","current":-11.8949,"twenty":-12.876517,"median":-10.189917,"eighty":-8.475423,"marketCap":87502117},{"date":"2025-01-24","current":-8.430366,"twenty":-12.823449,"median":-10.125219,"eighty":-8.466412,"marketCap":62016063},{"date":"2025-01-31","current":-5.629868,"twenty":-12.632281,"median":-9.850254,"eighty":-8.128675,"marketCap":41414837},{"date":"2025-02-07","current":-5.600996,"twenty":-12.558673,"median":-9.759676,"eighty":-7.471942,"marketCap":41202453},{"date":"2025-02-14","current":-5.745352,"twenty":-12.423258,"median":-9.716005,"eighty":-6.985183,"marketCap":42264372},{"date":"2025-02-21","current":-5.456641,"twenty":-12.370592,"median":-9.688508,"eighty":-6.36129,"marketCap":40140534},{"date":"2025-02-28","current":-4.734863,"twenty":-12.322192,"median":-9.575287,"eighty":-6.039722,"marketCap":34830939},{"date":"2025-03-07","current":-4.850347,"twenty":-12.19815,"median":-9.413543,"eighty":-5.818713,"marketCap":35680475},{"date":"2025-03-14","current":-4.619378,"twenty":-12.093217,"median":-9.316172,"eighty":-5.658739,"marketCap":33981404},{"date":"2025-03-21","current":-4.590507,"twenty":-12.033481,"median":-9.267973,"eighty":-5.589448,"marketCap":33769021},{"date":"2025-03-28","current":-4.677121,"twenty":-11.941094,"median":-9.085848,"eighty":-5.445093,"marketCap":34406172},{"date":"2025-04-04","current":-3.682014,"twenty":-11.842932,"median":-9.000397,"eighty":-5.346931,"marketCap":32707102},{"date":"2025-04-11","current":-2.731469,"twenty":-11.788323,"median":-8.747948,"eighty":-5.012916,"marketCap":24263468},{"date":"2025-04-17","current":-3.828934,"twenty":-11.749136,"median":-8.669517,"eighty":-4.901959,"marketCap":34012183},{"date":"2025-04-25","current":-3.926486,"twenty":-11.61974,"median":-8.601309,"eighty":-4.833024,"marketCap":34878735},{"date":"2025-05-02","current":-4.706906,"twenty":-11.475058,"median":-8.516979,"eighty":-4.792605,"marketCap":41811155},{"date":"2025-05-09","current":-4.804459,"twenty":-11.45771,"median":-8.491597,"eighty":-4.792605,"marketCap":42677707},{"date":"2025-05-16","current":-4.048427,"twenty":-11.438586,"median":-8.234384,"eighty":-4.718089,"marketCap":35961926},{"date":"2025-05-23","current":-2.933033,"twenty":-11.406237,"median":-8.124506,"eighty":-4.677121,"marketCap":33145630},{"date":"2025-05-30","current":-3.928425,"twenty":-11.380358,"median":-7.63641,"eighty":-4.64825,"marketCap":44394361},{"date":"2025-06-06","current":-4.052742,"twenty":-11.348009,"median":-7.333748,"eighty":-4.596281,"marketCap":45799246},{"date":"2025-06-13","current":-4.574874,"twenty":-11.315425,"median":-7.167274,"eighty":-4.590507,"marketCap":51699762}],"updateTime":1750032041808}}}